Menu

HIV Vaccines May Help Tamp Down Virus

A fraction of HIV patients in a small, uncontrolled study were able to stop antiretroviral therapy after receiving the immune boosters.

Feb 24, 2017
Kerry Grens

FLICKR, NIAIDSeveral HIV-positive volunteers have been off antiretroviral therapy for weeks—and in most cases, months—after receiving two experimental vaccines. Researchers reported the results of the 13-person trial, which did not include a control arm, at the Conference on Retroviruses and Opportunistic Infections in Seattle last week.

“The results are encouraging, but it is difficult to gauge what the effect of the procedure actually was because of the uncontrolled nature of the study and the fact that the people who remain off [ARVs] are, nevertheless, viremic,” Daniel Douek, an immunologist at the National Institute of Allergy and Infectious Diseases, told ScienceInsider.

All of the study participants had been on antiretroviral therapy before receiving two vaccines. Both immunizations were designed to direct cytotoxic T lymphocytes to attack conserved HIV proteins. Later, patients received a booster vaccine, along with a drug that activates latent HIV, before going off their HIV antiretroviral medications entirely.

According to news reports, eight volunteers in the study had to resume antiretroviral therapy, but the other five remain off the treatment—now, six weeks to seven months after cessation—with viral loads that appear to be under control.

“This is the first reported immune intervention demonstrating a manipulation of the [cytotoxic T lymphocyte] immunodominance pattern and a durable viremic control of HIV-1 infection in a large proportion of participants,” Beatriz Mothe of IrsiCaixa AIDS Research Institute in Barcelona, Spain, and her colleagues wrote in their presentation abstract.

“Should the current trends persist, it is hard to argue that the vaccine strategy did not do something,” Steven Deeks, an HIV researcher at the University of California, San Francisco, told Tech Times. “But controlled studies are needed.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.